Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Not Yet Recruiting NCT05661435

Utility of Remote Lung Auscultation in Transitions of Care After Pulmonary Exacerbations of COPD

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Sex: All
Ages: 35 Years – 75 Years
Enrollment: 40
Sponsor: Strados Labs, Inc.

Location: United States

Summary

Listening to breath sounds with the stethoscope/auscultation is used by pulmonary physicians in conjunction with pulmonary function, signs and symptoms, oxygen saturation and diagnostic testing to admit, follow and discharge patients from hospital. Of these, only auscultation routinely ceases upon discharge from Hospital. Healthcare utilization statistics have shown that for more than a decade, readmission after discharge for an exacerbation of COPD or severe asthma (or chronic heart failure) remains a major problem. The Strados RESP Biosensor has been designed to extend the range of lung sound recording both geographically and temporally to improve the standard of care when access to continuous monitoring has been replaced by periodic or no monitoring. The primary purpose of this study is to assess the associations between RESP Biosensor-acquired lung findings and subjective measures of respiratory symptoms as measured by validated measurement tools, and objective measure of respiratory physiology as determined by home spirometry

Eligibility Criteria

Inclusion Criteria:Males and females between the ages of 35 and 75 with documented physician-diagnosed COPDHospitalization with a primary diagnosis of COPD with exacerbation or pneumonia.Patient able and willing to provide informed consent.Patient can follow study procedures, including instructions for self-placement and operation of devicea. Patient has experience using a smartphoneAccessible by telehealth/telephone upon dischargePatient is able and willing to return to study site for study follow-up visits as necessaryExclusion Criteria:Patient unable or unwilling to provide informed consentDiagnosis of COPD is uncertainPlan for discharge to location other than the patient's home (eg, Nursing Home, Rehabilitation facility)Patient with end-stage medical condition with expected survival no more than 3 monthsHistory of adverse reaction or allergy to TegaDerm®Inaccessible by telehealth/telephone post discharge

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05661435). StuddyBuddy aggregates publicly available trial information.